denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: General Sessions
Session: ASH-EHA Joint Symposium: Failure of Targeted Cellular Immunotherapy and Hematopoietic Cell Transplant: Mechanisms and Mitigating Strategies
Session: ASH-EHA Joint Symposium: Failure of Targeted Cellular Immunotherapy and Hematopoietic Cell Transplant: Mechanisms and Mitigating Strategies
Sunday, December 6, 2020, 9:30 AM-10:30 AM
Disclosures: Mackall: Lyell Immunopharma: Consultancy, Current equity holder in private company; BMS: Consultancy; Allogene: Current equity holder in publicly-traded company; Apricity Health: Consultancy, Current equity holder in private company; Nektar Therapeutics: Consultancy; NeoImmune Tech: Consultancy.
See more of: ASH-EHA Joint Symposium: Failure of Targeted Cellular Immunotherapy and Hematopoietic Cell Transplant: Mechanisms and Mitigating Strategies
See more of: General Sessions
See more of: General Sessions
Previous Presentation
|
Next Presentation >>